1. Home
  2. AAOI vs NTLA Comparison

AAOI vs NTLA Comparison

Compare AAOI & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AAOI
  • NTLA
  • Stock Information
  • Founded
  • AAOI 1997
  • NTLA 2014
  • Country
  • AAOI United States
  • NTLA United States
  • Employees
  • AAOI 3309
  • NTLA N/A
  • Industry
  • AAOI Semiconductors
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • AAOI Technology
  • NTLA Health Care
  • Exchange
  • AAOI Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • AAOI 1.0B
  • NTLA 710.1M
  • IPO Year
  • AAOI 2013
  • NTLA 2016
  • Fundamental
  • Price
  • AAOI $15.52
  • NTLA $7.16
  • Analyst Decision
  • AAOI Buy
  • NTLA Buy
  • Analyst Count
  • AAOI 4
  • NTLA 20
  • Target Price
  • AAOI $25.50
  • NTLA $38.40
  • AVG Volume (30 Days)
  • AAOI 3.7M
  • NTLA 5.1M
  • Earning Date
  • AAOI 05-08-2025
  • NTLA 05-08-2025
  • Dividend Yield
  • AAOI N/A
  • NTLA N/A
  • EPS Growth
  • AAOI N/A
  • NTLA N/A
  • EPS
  • AAOI N/A
  • NTLA N/A
  • Revenue
  • AAOI $308,551,000.00
  • NTLA $45,569,000.00
  • Revenue This Year
  • AAOI $96.39
  • NTLA N/A
  • Revenue Next Year
  • AAOI $53.81
  • NTLA N/A
  • P/E Ratio
  • AAOI N/A
  • NTLA N/A
  • Revenue Growth
  • AAOI 50.30
  • NTLA N/A
  • 52 Week Low
  • AAOI $6.70
  • NTLA $5.90
  • 52 Week High
  • AAOI $44.50
  • NTLA $28.18
  • Technical
  • Relative Strength Index (RSI)
  • AAOI 45.46
  • NTLA 40.89
  • Support Level
  • AAOI $16.75
  • NTLA $6.83
  • Resistance Level
  • AAOI $19.20
  • NTLA $9.79
  • Average True Range (ATR)
  • AAOI 1.58
  • NTLA 0.60
  • MACD
  • AAOI -0.33
  • NTLA -0.21
  • Stochastic Oscillator
  • AAOI 7.46
  • NTLA 11.17

About AAOI Applied Optoelectronics Inc.

Applied Optoelectronics Inc is a provider of fiber-optic networking products, for four networking end-markets; internet data center, CATV, telecom, and FTTH. The Company designs and manufactures a wide range of optical communications products at varying levels of integration, from components, subassemblies, and modules to complete turn-key equipment. Through direct sales personnel, and manufacturing teams in the United States, China, and Taiwan, the company coordinates with customers to determine product design, qualifications, and performance. The Company has manufacturing and research and development facilities located in the U.S., Taiwan, and China.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: